Eli Lilly & Co., headquartered in Indianapolis, employs 43,000 staff and develops various pharmaceutical products, including diabetes, oncology, immunology, and neuroscience therapies, alongside radiopharmaceuticals through its subsidiary POINT Biopharma. The company manufactures and distributes products in the U.S., Europe, and Asia.
LLY has been in the news recently: JPMorgan has identified Eli Lilly as a potential leader for a market rebound, setting its price target at $1,100. This comes amid broader market commentary regarding economic conditions and stock performance.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
